Carl Porter

Dr. Porter is an Emeritus Professor of Molecular Pharmacology and Therapeutics at the Roswell Park Cancer Institute in Buffalo, New York where, until recently, he served as a Distinguished Member and as Leader of the Institute Therapeutics Program. He is an accomplished scientist and expert in anticancer targets and the pre-clinical development of anticancer agents. Dr. Porter has written and published nearly 200 scientific articles and has been awarded six patents in the areas of anticancer target and drug discovery. Over the course of his 35 yr career at Roswell Park, Dr. Porter garnered more than $16 million in grant support from the NCI and the Department of Defense. He received one of the first NCI-sponsored National Cancer Drug Discovery Grants and led a group of 6 prominent investigators from around the country for 12 years. Those efforts facilitated the discovery and development of two experimental anticancer drugs that progressed to clinical trial. He has consulted for pharmaceutical companies including Ciba-Geigy (now Novartis) and Warner Lambert Parke Davis (now Pfizer). He has served on various editorial boards including Cancer Research and participated in NIH review activities including site visits and program grant review panels, many of which he chaired. Dr Porter has a M.S. in microbiology from West Virginia University and a Ph.D. in neuropathology from the State University of New York at Buffalo. He has mentored more than 10 doctoral students.